Population pharmacokinetic modeling of gentamicin in dogs
Authors:
- Kevellyn Silveira Gomes MartinsKevellyn Silveira Gomes Martins
- Larissa Alexandra FélixLFLarissa Alexandra Félix
- Lucas Wamser Fonseca GonzagaLGLucas Wamser Fonseca Gonzaga
- Karina Krauss Ferraz VasconcelosKVKarina Krauss Ferraz Vasconcelos
- Diego DíazDDDiego Díaz
- João Vitor Fernandes Cotrim de AlmeidaJAJoão Vitor Fernandes Cotrim de Almeida
- Aline Carvalho PereiraAPAline Carvalho Pereira
- Marcos FerranteMFMarcos Ferrante
Open Access
- 27 February 2026
- journal article
- Published by Universidade Estadual de Londrina in Semina: Ciências Agrárias
- Vol. 47 (1) , 289-306
Abstract
This study used population pharmacokinetic (popPK) modeling to predict therapeutic efficacy and assess nephrotoxicity risk associated with gentamicin administration in dogs. The model was developed in Monolix 2024 R1 (Lixoft SAS, Simulations Plus Company) using plasma concentrationtime data obtained from the literature. Monte Carlo simulations were subsequently performed in Simulx 2024 (Lixoft SAS, Simulations Plus Company) for gentamicin doses of 2, 4, 6, and 8 mg kg-1 to evaluate therapeutic target attainment and exposure associated with nephrotoxicity risk. The model that best described the observed data was a two-compartment model with linear elimination. Predicted therapeutic efficacy was assessed using the Probability of Target Attainment (PTA) based on the PK/PD target fCmax/MIC ≥ 10 across a range of minimum inhibitory concentrations (MICs). Nephrotoxicity risk was evaluated according to the duration for which plasma gentamicin concentrations remained above the primary nephrotoxicity-risk threshold of 2 μg mL-1. The 8 mg kg-1 regimen achieved PTA values ≥ 90% for pathogens with MIC ≤ 2.0 μg mL-1 and represented the highest-performing simulated regimen among those evaluated. For this regimen, the mean time above the 2 μg mL-1 nephrotoxicity-risk threshold ranged from 4 to 8 hours. These findings support the use of gentamicin against pathogens with MICs ≤ 2 μg mL-1 when administered using extended dosing intervals. However, dose and interval adjustments may be required in critically ill patients. Overall, the popPK approach provides a useful framework for precision dosing, supporting improved predicted efficacy and safety across different dosing regimens.Keywords
This publication has 42 references indexed in Scilit:
- Clinical safety and efficacy of a single‐dose gentamicin, posaconazole and mometasone furoate otic suspension for treatment of canine otitis externaVeterinary Record, 2024
- Pharmacodynamic model of slow reversible binding and its applications in pharmacokinetic/pharmacodynamic modeling: review and tutorialJournal of Pharmacokinetics and Pharmacodynamics, 2022
- Clinical Pharmacokinetics of Gentamicin in Various Patient Populations and Consequences for Optimal Dosing for Gram-Negative Infections: An Updated ReviewClinical Pharmacokinetics, 2022
- Efficient Pharmacokinetic Modeling Workflow With the MonolixSuite: A Case Study of RemifentanilCPT: Pharmacometrics & Systems Pharmacology, 2020
- Extended-interval Dosing of Gentamicin in Premature Neonates Born at 7 Days of ageClinical Therapeutics, 2017
- Model Evaluation of Continuous Data Pharmacometric Models: Metrics and GraphicsCPT: Pharmacometrics & Systems Pharmacology, 2016
- Enhanced Method for Diagnosing Pharmacometric Models: Random Sampling from Conditional DistributionsPharmaceutical Research, 2016
- Clinical pharmacokinetics of aminoglycosides in the neonate: a reviewEuropean Journal of Clinical Pharmacology, 2008
- Exponential Intravenous Infusions in Toxicological Studies: Achieving Identical Serum Drug Concentration Profiles in Individuals with Altered Pharmacokinetic StatesJournal of Pharmaceutical Sciences, 1986
- Pharmacokinetics of Piperacillin and Gentamicin Following Intravenous Administration to DogsJournal of Pharmaceutical Sciences, 1983